All Stories

  1. Widespread Pain Phenotypes Impact Treatment Efficacy Results in Randomized Clinical Trials for Interstitial Cystitis/ Bladder Pain Syndrome: A MAPP Network Study
  2. Relationship Between Central Obesity, General Obesity, Overactive Bladder Syndrome and Urinary Incontinence Among Male and Female Patients Seeking Care for Their Lower Urinary Tract Symptoms
  3. Changes in brain white matter structure are associated with urine proteins in urologic chronic pelvic pain syndrome (UCPPS): A MAPP Network study
  4. Symptom Based Clustering of Women in the LURN Observational Cohort Study
  5. The LURN Research Network Neuroimaging and Sensory Testing (NIST) Study: Design, protocols, and operations
  6. Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary Incontinence
  7. Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones
  8. Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study
  9. Research Needs to Understand Self-Management of Lower Urinary Tract Symptoms: Summary of NIDDK Workshop
  10. NIH research opportunities for the prevention and treatment for chronic conditions
  11. Bowel function, sexual function, and symptoms of pelvic organ prolapse in women with and without urinary incontinence
  12. MP27-09 RELATIONSHIPS BETWEEN METABOLIC FACTORS, URINARY INCONTINENCE AND OVERACTIVE BLADDER SYMPTOMS AMONG MEN AND WOMEN IN THE LURN OBSERVATIONAL COHORT STUDY
  13. Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study
  14. Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods Study
  15. Evidence of the Impact of Diet, Fluid Intake, Caffeine, Alcohol and Tobacco on Lower Urinary Tract Symptoms: A Systematic Review
  16. Re: Top cited articles in urology from Turkey
  17. Design and challenges of a randomized clinical trial of medical expulsive therapy (tamsulosin) for urolithiasis in the emergency department
  18. Symptom Variability and Early Symptom Regression in the MAPP Study: A Prospective Study of Urological Chronic Pelvic Pain Syndrome
  19. Advancing a Comprehensive Approach to the Study of Lower Urinary Tract Symptoms
  20. Role of Transition Zone Index in the Prediction of Clinical Benign Prostatic Hyperplasia
  21. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement
  22. Symptoms of Lower Urinary Tract Dysfunction Research Network
  23. Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health
  24. Do we need new patient reported measures to evaluate lower urinary tract dysfunction?
  25. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
  26. Quality of Acute Care for Patients With Urinary Stones in the United States
  27. Urinary Stone Disease: Progress, Status, and Needs
  28. Relationship between Chronic Nonurological Associated Somatic Syndromes and Symptom Severity in Urological Chronic Pelvic Pain Syndromes: Baseline Evaluation of the MAPP Study
  29. Emergency Department Revisits for Patients with Kidney Stones in California
  30. The International Prostate Forum introduction and history
  31. Association of metallothionein expression and clinical response to cisplatin based chemotherapy in testicular germ cell tumors
  32. Cross-Sectional and Longitudinal Associations of Sexual Function with Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia
  33. The MAPP research network: a novel study of urologic chronic pelvic pain syndromes
  34. The MAPP research network: design, patient characterization and operations
  35. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer
  36. Comparative Effectiveness of Shock Wave Lithotripsy and Ureteroscopy for Treating Patients With Kidney Stones
  37. Change in Sexual Function in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Associated with Long-Term Treatment with Doxazosin, Finasteride and Combined Therapy
  38. Immunoglobulin G4–related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer
  39. Genito-Urological Cancers in Elderly Patients
  40. Reply to Jérôme Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4–related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. Eur ...
  41. Can We Change Patient Behaviors to Improve Urological Health?
  42. Long-Term Effects of Doxazosin, Finasteride and Combination Therapy on Quality of Life in Men with Benign Prostatic Hyperplasia
  43. Emergency department visits, use of imaging, and drugs for urolithiasis have increased in the United States
  44. Somatostatin receptor expression in prostate carcinoma: the urological pathologist’s role in the era of personalised medicine
  45. Active surveillance for small renal tumors: Have clinical concerns been addressed so far?
  46. Positive Surgical Margins After Nephron-Sparing Surgery
  47. Lymphocytic vasculitis of the prostate transition zone
  48. Unclassified renal cell carcinoma: a report of 56 cases
  49. Basic Research in Kidney Cancer
  50. Renal Cell Carcinoma: A Changing Paradigm With a Need for Consensus
  51. ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease
  52. International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma
  53. Contemporary Management of Small Renal Masses
  54. Re: Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin Plus Isoniazid in Patients With Intermediate- and Hig...
  55. International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
  56. Management of advanced prostate cancer – new drugs
  57. Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility
  58. 716 PHASE III STUDY OF INTERMITTENT MAB VS CONTINUOS MAB
  59. Toxicities of Targeted Therapy and Their Management in Kidney Cancer
  60. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 tria...
  61. Reply to Kiril Trpkov, Asli Yilmaz’ Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patien...
  62. Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Tria...
  63. Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited
  64. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use
  65. Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma
  66. Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials
  67. Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors
  68. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient’s Pathology and Clinical Reports
  69. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-ri...
  70. Editorial Comment on: Predicting Occult Multifocality of Renal Cell Carcinoma
  71. Re: Matthias May, Sabine Brookman-Amissah, Jan Roigas, et al. Prognostic Accuracy of Individual Uropathologists in Noninvasive Urinary Bladder Carcinoma: A Multicentre Study Comparing the 1973 and 2004 World Health Organisation Classifications. Eur Uro...
  72. Reply to Tomasso Cai, Lorenzo Giuseppe Luciani and Gianni Malossini’s Letter to the Editor re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comp...
  73. Ablative therapies in the treatment of small renal tumors: How far from standard of care?
  74. Reply from Authors re: Marko Babjuk. New Insights in Intravesical Treatment for Intermediate- and High-Risk Non–Muscle-Invasive Urothelial Bladder Carcinoma. Eur Urol 2010;57:774–6
  75. The Changing Face of Renal-Cell Carcinoma
  76. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Ri...
  77. Reply to José I. Lopéz's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and ...
  78. A Critical Analysis of the Actual Role of Minimally Invasive Surgery and Active Surveillance for Kidney Cancer
  79. The Motion: Cryotherapy is an Efficient Alternative for Kidney Cancer
  80. Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better
  81. What is new in kidney cancer?
  82. Kidney cancer in the elderly
  83. Genetic profiles in renal tumors
  84. Prostate Cancer: New Insights into Minimal and Localised Disease: Active Surveillance
  85. Secondary neoplasms of the urinary system and male genital organs
  86. Prediction of Prostatic Involvement by Urothelial Carcinoma in Radical Cystoprostatectomy for Bladder Cancer
  87. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?
  88. Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?
  89. Neuroendocrine tumours of the urinary system and male genital organs: clinical significance
  90. Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group
  91. Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique
  92. 2009 update on the classification of renal epithelial tumors in adults
  93. Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?
  94. Urologic oncology in southern Europe: Perceived problems and current plans
  95. Editorial Comment on: Prognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal Cell Carcinoma
  96. Multigene Methylation Analysis of Conventional Renal Cell Carcinoma
  97. Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications
  98. Editorial Comment on: Results of Endoluminal Occlusion of the Inferior Vena Cava During Radical Nephrectomy and Thrombectomy
  99. Rare and unusual histological variants of prostatic carcinoma: clinical significance
  100. Will We Be Able to “Cure” Metastatic Renal Cell Carcinoma Like We Cure Testicular Tumours?
  101. Editorial Comment on: Preservation of Renal Function Following Partial or Radical Nephrectomy Using 24-Hour Creatinine Clearance
  102. Splitting and Lumping Adult Renal Epithelial Tumors Can Help the Urologists in the Prognostic Risk Stratification and in the Treatment Decision-Making
  103. Open Partial Nephrectomy in the Management of Small Renal Masses
  104. Chairmen's Summary
  105. Renal Cell Carcinoma: Overview
  106. A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate
  107. Reply to Apostolos P. Labanaris et al's Letter to the Editor re: Ziya Kirkali and Hein Van Poppel. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. Eur Urol 2007;52:658–62
  108. There has to be a Way
  109. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion
  110. Editorial: Special Issue. Current Treatment of Localized Renal Cancer
  111. Rebuttal from Authors re: Carlo Terrone, Alessandro Volpe. The Role of Pathology for Clinical Decision-Making in Renal Cell Carcinoma is Increasing. Eur Urol 2007;51:1166–8
  112. What Does the Urologist Expect from the Pathologist (and What Can the Pathologists Give) in Reporting on Adult Kidney Tumour Specimens?
  113. Histologic Grading of Noninvasive Papillary Urothelial Neoplasms
  114. Re: Nephroureterectomy for Treating Upper Urinary Tract Transitional Cell Carcinoma. Time to Change the Treatment Paradigm?
  115. The motion: Open partial nephrectomy is the standard of care for small resectable solid renal masses
  116. Editorial: Special Issue. Current Treatment of Localized Renal Cancer
  117. Editorial: Superficial Bladder Cancer
  118. Reply to Dr Özdemir’s Letter to the Editor re: Burcin Tuna, Kutsal Yorukoglu, Mehtat Unlu, M. Ugur Mungan and Ziya Kirkali, Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas. Eur Urol. 2006;50:530–34
  119. Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas
  120. Puigvert: A Man with a Vision—Nephron-Sparing Surgery 30 Years Ago in Europe
  121. Expression of COX-2 in Normal and Pyelonephritic Kidney, Renal Intraepithelial Neoplasia, and Renal Cell Carcinoma
  122. Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate
  123. 2004 WHO Classification of the Renal Tumors of the Adults
  124. Expression of Cathepsin D in Bladder Carcinoma: Correlation with Pathological Features and Serum Cystatin C Levels
  125. Are We Really Making an Advance in the Treatment of Metastatic Renal Cell Carcinoma?
  126. Beyond Skeletal-Related Events
  127. Superficial Urothelial Cancer in the Prostatic Urethra
  128. Superficial Urothelial Cancer in the Prostatic Urethra
  129. Editorial: Superficial Bladder Cancer
  130. The Future of Oncological Urology in Europe: Are we Prepared?
  131. Bladder cancer: Epidemiology, staging and grading, and diagnosis
  132. Risk Factors for Mucosal Prostatic Urethral Involvement in Superficial Transitional Cell Carcinoma of the Bladder
  133. Echo Contrast-Enhanced Power Doppler Ultrasonography for Assessment of Angiogenesis in Renal Cell Carcinoma
  134. Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma?
  135. 1,25 Dihydroxyvitamin D Receptor Expression in Superficial Transitional Cell Carcinoma of the Bladder: A Possible Prognostic Factor?
  136. Significance of COX-2 expression in human renal cell carcinoma
  137. Urothelial carcinoma of the bladder with trophoblastic differentiation: A case report
  138. Significance of heat shock protein-27 expression in patients with renal cell carcinoma
  139. Handling and Pathology Reporting of Adrenal Gland Specimens
  140. Conservative Management of Mucosal Prostatic Urethral Involvement in Patients with Superficial Transitional Cell Carcinoma of the Bladder
  141. Handling and Pathology Reporting of Renal Tumor Specimens
  142. Developments in Organ Preserving Treatments for Renal Cell Cancer: Open Surgery
  143. Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder
  144. Premalignant lesions of the kidney share the same genetics changes as conventional renal cell carcinoma
  145. Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder
  146. Clinical Aspects of Renal Cell Carcinoma
  147. Renal cell carcinoma: new prognostic factors?
  148. Bone Mineral Density and Biochemical Markers of Bone in Patients With Idiopathic Hypercalciuria
  149. RE: Etiology of Spontaneous Perirenal Hemorrhage: A Meta-Analysis
  150. Transitional cell carcinoma of the ureter and renal pelvis
  151. Primary renal lymphoma of mucosa-associated lymphoid tissue
  152. Expression of p53 and mdm2 and Their Significance in Recurrence of Superficial Bladder Cancer
  153. Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer
  154. RE: THE PATIENT WITH CHRONIC EPIDIDYMITIS: CHARACTERIZATION OF AN ENIGMATIC SYNDROME
  155. RE: THE PATIENT WITH CHRONIC EPIDIDYMITIS: CHARACTERIZATION OF AN ENIGMATIC SYNDROME
  156. Prognostic significance of nuclear morphometry in renal cell carcinoma
  157. Prognostic Significance of Estrogen Receptor Expression in Superficial Transitional Cell Carcinoma of the Urinary Bladder
  158. Management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder
  159. Phase III study of intermittent MAB versus continuous MAB international cooperative study
  160. A Prospective Survey of Surgical Approaches in Clinically Localized Renal Cell Carcinoma--A Preliminary Attempt at Surgical Quality Control
  161. Testis sparing surgery for the treatment of a sequential bilateral testicular germ cell tumor
  162. Proliferative activity, angiogenesis and nuclear morphometry in renal cell carcinoma
  163. Recent advances in kidney cancer and metastatic disease
  164. Vertebral Fracture Associated with Shockwave Lithotripsy in a Patient with Granulomatous Spondylitis
  165. INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-...
  166. Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder?
  167. METALLOTHIONEIN EXPRESSION IN RENAL CELL CARCINOMA: SUBCELLULAR LOCALIZATION AND PROGNOSTIC SIGNIFICANCE
  168. Quality control of radical prostatectomy
  169. Premalignant Lesions in the Kidney
  170. Expression of PS2 Protein and Its Relation with the Ki–67 Proliferative Indices and Tumor Recurrence in Superficial Bladder Carcinomas
  171. Renal Cancer
  172. Significance of Tissue Laminin P<sub>1</sub> Elastase and Fibronectin Levels in Transitional Cell Carcinoma of the Bladder
  173. Ganglion cells in the human prostate
  174. Prognostic Significance of Microvascular Invasion in Localized Renal Cell Carcinoma
  175. RE: RECURRENT BILATERAL AMIODARONE INDUCED EPIDIDYMITIS
  176. Prognostic significance of angiogenesis and immunoreactivity of cathepsin d and type IV collagen in high-grade stage T1 primary bladder cancer
  177. PHARMACOLOGICAL ANALYSIS OF 5-HYDROXYTRYPTAMINE EFFECTS ON HUMAN ISOLATED URETER
  178. Tubular dysplasia and carcinoma in situ: precursors of renal cell carcinoma
  179. RE
  180. RE: URINARY TRACT CANCER AND HEREDITARY NONPOLYPOSIS COLORECTAL CANCER
  181. Comparison of Microvascularization in Diagnostic Needle Biopsies and Radical Prostatectomies in Prostate Carcinoma
  182. Radical Nephrectomy with and without Lymph Node Dissection: Preliminary Results of the EORTC Randomized Phase III Protocol 30881
  183. Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume
  184. Renal Effects of Carbon Dioxide Insufflation in Rabbit Pneumoretroperitoneum Model
  185. Volume-weighted mean nuclear volume in renal cell carcinoma
  186. RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA
  187. RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA
  188. Renal Cell Carcinoma with Gallbladder Metastasis
  189. Investigation of p53, c-erbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters
  190. Is Magnetic Resonance Imaging Necessary in the Staging of Prostate Cancer?
  191. Locally Recurrent Paratesticular Rhabdomyosarcoma Treated with Surgery and Radiotherapy
  192. Testicular Microlithiasis Associated with Teratocarcinoma and Intratubular Germ Cell Neoplasia: A Case Report
  193. Contractility Changes of the Deep Dorsal Penile Vein Due to Serotonin
  194. Ignificance of serum lam1nin P1 values in patients with transitional cell carcinoma of the bladder
  195. Effect of Extracorporeal Shockwave Lithotripsy on Plasma and Urine Endothelin Concentrations
  196. Bellini duct (collecting duct) carcinoma of the kidney
  197. Primary Kaposi's sarcoma of the glans penis
  198. Effectiveness of Extracorporeal Shockwave Lithotripsy in the Management of Stone-Bearing Horseshoe Kidneys
  199. 99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between99mTc-MIBI uptake and P-alvcoprotein expression in tumour tissue
  200. Cisplatin and Etoposide Chemotherapy in the Treatment of Adult Wilms’ Tumor
  201. The Effect of Extracorporeal Electromagnetic Shock Waves on the Morphology and Contractility of Rabbit Ureter
  202. The Effect of Extracorporeal Electromagnetic Shock Waves on the Morphology and Contractility of Rabbit Ureter
  203. Prostatic carcinoma presenting with painless parotid mass
  204. Influence of Serotonin on the Human Ureter: An in vitro Pharmacological Study
  205. Effect of Ejaculation on Prostate-Specific Antigen Levels in Normal Men
  206. Ferritin: A Tumor Marker Expressed by Renal Cell Carcinoma
  207. The effect of extracorporeal shock wave lithotripsy on pancreatic enzymes
  208. Magnetic resonance imaging in the staging of renal cell carcinoma
  209. Does Respiratory Gating Improve Extracorporeal Shockwave Lithotripsy Results?
  210. Beh�et's disease: Urogynecological manifestations in women
  211. Open stone surgery: Is it still a preferable procedure in the management of staghorn calculi?
  212. The effect of extracorporeal electromagnetic shock waves on renal proximal tubular function
  213. Primary signet-ring cell carcinoma of the bladder
  214. Are Obstructing Ureteral Stones More Difficult to Treat with Extracorporeal Electromagnetic Shock Wave Lithotripsy?*
  215. Extracorporeal Electromagnetic Shock Wave Lithotripsy of Ureteric Stones in Situ
  216. Carcinoma of the prostate and HLA antigens
  217. Carcinoma of the bladder in patients less than 40 years old
  218. Urological Aspects of Behcet's Disease
  219. Cysts of the Prostate, Seminal Vesicles and Diverticulum of the Ejaculatory Ducts
  220. Silent Testicular Metastasis from Carcinoma of the Prostate
  221. Tunica Vaginalis: an Aid in Hypospadias Surgery
  222. Androgen receptors in transitional cell carcinoma
  223. HLA Antigens and Transitional Cell Carcinoma of the Bladder
  224. Androgen Receptors - A Method to Measure Functional Behaviour in Human Prostatic Cancer
  225. Epidemiological Case-Control Study on the Etiology of Bladder Cancer in Turkey
  226. Urothelial Tumours of the Upper Urinary Tract
  227. Bladder agenesis
  228. Ureterorenoscopy: A new approach in the diagnosis and treatment of upper urinary tract disorders
  229. Amiodarone-Induced Sterile Epididymitis
  230. Blood Groups and Transitional Cell Carcinoma of the Upper Urinary Tract
  231. Spontaneous Kidney Rupture in Polyarteritis nodosa Report of Four Cases
  232. The use of oxybutynin in urological practice
  233. Ureteric perforation after ureteroscopy
  234. Androgen receptors in TCC
  235. Unusual Metastases of Renal Cell Carcinoma
  236. The role of delay in stage III testicular tumours
  237. The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate
  238. The Role of Delay in Stage-Ill Testicular Tumors
  239. Haemoglobin F Levels in Patients with Testicular Tumours
  240. Experience with Treatment of Nonseminomatous Germ Cell Tumors of Testis in Turkey
  241. Advanced Tumors: Tumor Thrombus